BOTOX-UROLOGY
Drug
Allergan Inc.
Total Payments
$1.2M
Transactions
354
Doctors
156
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $1.2M | 354 | 156 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 173 | 98.9% |
| Food and Beverage | $12,228 | 178 | 1.0% |
| Travel and Lodging | $944.53 | 3 | 0.1% |
Payments by Type
Research
$1.2M
173 transactions
General
$13,172
181 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE AN ENHANCED INJECTION PARADIGM FOR ONABOTULINUMTOXINA BOTOX IN THE TREATMENT OF OVERACTIVE BLADDER IN PATIENTS WITH URINARY INCONTINENCE | Allergan Inc. | $1.1M | 1 |
| Multicenter, Double-Blind, Randomized, Placebo Controlled, Parallel-group, Study on the Safety and Pharmacodynamic Response of Botox in Subjects with Moderate to Severe Dynamic Glabellar Lines | Allergan Inc. | $29,553 | 2 |
| DETERMINE VE CUTOFF RATIOS THAT PREDICT POST-PROCEDURE URINARY RETENTION REQUIRING CATHETERIZATION, AFTER TREATMENT WITH THERAPEUTIC DOSES OF BOTOX | Allergan Inc. | $23,642 | 0 |
| A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Single Treatment, 2-Stage, Dose finding Study Evaluating the Efficacy and Safety of Botox Intravesical Installation in Participants with Overactive Bladder and Urinary Incontinence. | Allergan Inc. | $13,950 | 0 |
Top Doctors Receiving Payments for BOTOX-UROLOGY
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chapel Hill, NC | $1.2M | 170 |
| , M.D | Obstetrics & Gynecology | Durham, NC | $3,554 | 1 |
| , M.D | Surgery | Boca Raton, FL | $3,078 | 1 |
| , M.D | Dermatology | Solana Beach, CA | $2,914 | 1 |
| , MD | Urology | New York, NY | $1,720 | 9 |
| , M.D | Urogynecology and Reconstructive Pelvic Surgery | New York, NY | $260.75 | 2 |
| , M.D | Student in an Organized Health Care Education/Training Program | Washington, DC | $255.35 | 2 |
| , MD | Obstetrics & Gynecology | Washington, DC | $255.35 | 2 |
| , MD | Urology | Albany, NY | $240.76 | 2 |
| , M.D | Urogynecology and Reconstructive Pelvic Surgery | Los Angeles, CA | $215.82 | 2 |
| , M.D | Gynecology | Overland Park, KS | $194.46 | 3 |
| , MD | Urology | Brighton, MA | $178.86 | 5 |
| , D.O | Urology | Sewell, NJ | $173.96 | 2 |
| , MD | Urology | Plainview, NY | $157.78 | 2 |
| , MD | Urogynecology and Reconstructive Pelvic Surgery | Washington, DC | $145.56 | 1 |
| , M.D | Obstetrics & Gynecology | Madison, WI | $145.56 | 1 |
| , MD | Urogynecology and Reconstructive Pelvic Surgery | Albany, NY | $139.34 | 1 |
| , D.O | Urology | Tucson, AZ | $134.28 | 1 |
| , MD | Specialist | Tucson, AZ | $134.28 | 1 |
| , M.D | Urology | Charleston, SC | $134.28 | 1 |
| , MD | Urology | East Orange, NJ | $134.28 | 1 |
| , DO | Student in an Organized Health Care Education/Training Program | Omaha, NE | $134.28 | 1 |
| , B SC MBBS MS FRACS | Student in an Organized Health Care Education/Training Program | — | $134.28 | 1 |
| , M.D | Urology | Charleston, SC | $134.28 | 1 |
| , M.D | Surgery | New Haven, CT | $134.28 | 1 |
Ad
Manufacturing Companies
- Allergan Inc. $1.2M
Product Information
- Type Drug
- Total Payments $1.2M
- Total Doctors 156
- Transactions 354
About BOTOX-UROLOGY
BOTOX-UROLOGY is a drug associated with $1.2M in payments to 156 healthcare providers, recorded across 354 transactions in the CMS Open Payments database. The primary manufacturer is Allergan Inc..
Payment data is available from 2017 to 2017. In 2017, $1.2M was paid across 354 transactions to 156 doctors.
The most common payment nature for BOTOX-UROLOGY is "Unspecified" ($1.2M, 98.9% of total).
BOTOX-UROLOGY is associated with 4 research studies, including "A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE AN ENHANCED INJECTION PARADIGM FOR ONABOTULINUMTOXINA BOTOX IN THE TREATMENT OF OVERACTIVE BLADDER IN PATIENTS WITH URINARY INCONTINENCE" ($1.1M).